ArticleBMJ open2025
Association of herpes zoster vaccination and cardiovascular risk in patients with diabetes: long-term insights from a retrospective cohort study.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Adult vaccination coverage and missed preventive care opportunities among Filipino adults with diabetes: A cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Herpes Zoster Vaccination as Cardiovascular Prevention in Adults with Heart Disease.Cardiovascular drugs and therapy · 2026Review
- Recombinant zoster vaccine and risk of kidney failure, cardiovascular, and mortality in patients with chronic kidney disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Impact of herpes zoster and post-zoster SGLT2 inhibitors initiation on cardiorenal outcomes in type 2 diabetes mellitus.BMC endocrine disorders · 2026Article
- Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review.CJC open · 2025Review
- The Big Data Era in Cardiology and Cardiovascular Medicine: Advanced Analytics for Truly Personalized Care.Diagnostics (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHerpes zoster (HZ) infection is associated with a higher risk of major adverse cardiovascular events (MACE), including stroke and coronary artery disease (CAD). Patients with diabetes are at an increased risk of MACE, highlighting the importance of studying this population to assess the potential protective effects of HZ vaccination. This study aims to investigate the risk of MACE after HZ vaccination in patients with diabetes.
designRetrospective cohort study.
settingCommunity-based population in the USA.
participantsUsing the TriNetX database, the study included 4.9 million patients with diabetes from 2006 to 2022. It established two cohorts: 68 178 patients in the HZ vaccination (comprising any HZ vaccine, Shingrix or Zostavax) and 4 835 246 patients in the no HZ vaccination group. After excluding patients with a history of MACE, immune disease and complications of HZ prior to the index date, the study cohort was reduced to 45 960 patients. Propensity score matching, accounting for age, sex, race, socio-economic status and disease comorbidities, was conducted to minimise study bias.
interventionsHZ vaccination. OUTCOME MEASURES: MACE outcomes are defined as the first occurrence of CAD or stroke. Comparative risk analysis was conducted using HRs.
resultsPost matching, the mean patient age was 63.5 years, with 49.2% females. The incidence rate of MACE was lower among vaccinated patients compared with unvaccinated individuals, with an HR of 0.76 (0.72-0.79). For secondary endpoints, the HRs were 0.73 (0.69-0.78) for CAD, 0.79 (0.74-0.84) for stroke and 0.54 (0.52-0.57) for all-cause mortality. These protective effects remained consistent across different age groups, sexes and diabetes types, supporting the potential benefit of HZ vaccination in reducing cardiovascular risk.
conclusionsHZ vaccination is associated with a lower risk of MACE in patients with diabetes. Further prospective studies are critically needed to confirm this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.